Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Must have received: proteasome inhibitor

Patients have received at least 3 prior MM treatment regimens containing at least one proteasome inhibitor and one immunomodulator

Must have received: immunomodulator

Patients have received at least 3 prior MM treatment regimens containing at least one proteasome inhibitor and one immunomodulator

Cannot have received: CAR-T cell therapy

Subjects who have received CAR-T treatment or other genetically modified cell therapies

Cannot have received: BCMA-targeted therapy

as well as other BCMA-targeting drugs

Cannot have received: hematopoietic stem cell transplant

Exception: autologous transplant is not possible or relapsed after autologous transplant is allowed; any hematopoietic stem cell transplant performed within the first two months of screening is excluded

Subjects with any hematopoietic stem cell transplant performed within the first two months of screening

Cannot have received: immunosuppressive therapy

Exception: due to graft-versus-host disease performed during the screening period

any immunosuppressive therapy due to graft-versus-host disease performed during the screening period

Cannot have received: systemic steroid

Exception: except inhalation or topical use

Subjects who were receiving systemic steroid treatment within 14 days before the screening period and who were judged by the investigator to require long-term use of systemic steroid therapy during treatment (except inhalation or topical use)

Cannot have received: systemic anti-tumor therapy

Exception: except for local anti-tumor therapy

subjects who received any systemic anti-tumor therapy (except for local anti-tumor therapy)

Cannot have received: live attenuated vaccine

Subjects who have received live attenuated vaccine within 4 weeks prior to apheresis